BRD2 and ovarian hyperstimulation syndrome: Pooling the data in the trials did not show a significant difference between the r-LH supplementation group and the r-FSH alone group regarding the total days of stimulation per treatment cycle (two trials: WMD -0.05, 95% CI -0.73 to 0.64), incidence of OHSS (three trials: OR 1.77, 95% CI 0.38 to 8.32), serum progesterone level on hCG day (WMD -0.04, 95% CI -0.46 to -0.38).